Compare Ascendis Pharma A/S (ASND) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Wipro Limited — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Wipro Limited trades at $1.88 (market cap $18.38B). The key difference: Ascendis Pharma A/S and Wipro Limited are close in size by market cap, and Wipro Limited pays a 10.25% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WIT | |
|---|---|---|
Market Cap | $17.74B | $18.38B |
Sector | Health | Technology |
52-Week High | $277.18 | $3.06 |
52-Week Low | $163.32 | $1.82 |
Enterprise Value | $18.11B | $14.77B |
Dividend Yield | — | 10.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
WIT trades at $1.87, up 1.08% today, but faces bearish technical signals with recent earnings misses in Q3 2025, Q4 2025, and Q1 2026. Fundamentals show solid profitability with a 14.25% net margin and 15.4% ROE, while valuation metrics like a P/E of 14.05 appear reasonable. Recent news highlights AI partnerships with ServiceNow and Anthropic, though weak Q2 2026 guidance has pressured sentiment.
The outlook is cautious with mixed analyst ratings (19% buy, 48% hold, 33% sell) and near-term revenue headwinds. Investment opportunities lie in AI-driven growth initiatives, but risks include execution challenges and competitive pressures in the IT services sector. Cash flow remains strong at $25.02B net for 2025, supporting financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
